Ignite Creation Date:
2024-05-06 @ 2:51 AM
Last Modification Date:
2024-10-26 @ 11:24 AM
Study NCT ID:
NCT02140814
Status:
COMPLETED
Last Update Posted:
2016-12-01
First Post:
2014-05-14
Brief Title:
Uncontrolled Open Label Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease
Sponsor:
Alan Yu MB BChir
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
Uncontrolled Open Label Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NIAC-PKD1
Brief Summary:
The goal of this pilot study is to evaluate the feasibility of administering niacinamide to patients with autosomal dominant polycystic kidney disease to develop methods to assess the biological efficacy of niacinamide and to perform a preliminary exploration of its clinical effect on kidney cyst growth and kidney function
Detailed Description:
Niacinamide is a form of vitamin B3 Vitamin B3 is found in many foods including yeast meat fish milk eggs green vegetables beans and cereal grains Recent studies in mice have shown that niacinamide at high doses may slow kidney cyst growth from polycystic kidney disease PKD
By doing this study the researchers will determine if a larger long-term study to test whether niacinamide slows progression of PKD is justified
By doing this study the researchers will determine if a larger long-term study to test whether niacinamide slows progression of PKD is justified
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None